GT BIOPHARMA INC (GTBP): Hedge Fund Ownership & Smart Money Signals (Q4 2025)

GT BIOPHARMA INC (GTBP)

37 + Investors. Track Smart Money conviction in GTBP. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — GTBP

Based on 37 hedge funds · latest filing: 2025 Q4 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q

For 1 consecutive quarter, more hedge funds added GTBP than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

37 hedge funds hold GTBP right now — the highest count in 2.2 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +131% more funds vs a year ago

fund count last 6Q

+21 new funds entered over the past year (+131% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟢

More buyers than sellers — 68% buying

25 buying12 selling

Last quarter: 25 funds were net buyers (22 opened a brand new position + 3 added to an existing one). Only 12 were sellers (7 trimmed + 5 sold completely). A clear majority buying is a strong confirmation signal.

📈

More new buyers each quarter (+19 vs last Q)

new funds entering per quarter

Funds opening a new GTBP position: 3 → 4 → 3 → 22. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

🔄

Mostly new holders — 65% entered in last year

■ 0% conviction (2yr+) ■ 35% medium ■ 65% new

Only 0 funds (0%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

💰

Value +68% but shares only +29% — price-driven

Value

+68%

+29%

Last quarter: the total dollar value of institutional holdings rose +68%, but actual share count only changed +29%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

🚀

Acceleration phase — new buyers rushing in

3 → 3 → 4 → 3 → 22 new funds/Q

New funds entering each quarter: 3 → 4 → 3 → 22. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.

🌱

Early stage — 68% of holders entered in last year

■ 0% veterans ■ 32% 1-2yr ■ 68% new

Of 37 current holders: 25 (68%) entered in the past year, only 0 (0%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.

📋

Smaller funds dominant — 16% AUM from top-100

16% from top-100 AUM funds

8 of 37 holders rank in the top 100 by AUM, but together hold only 16% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

5.7

out of 10

Moderate Exit Risk

Exit risk score 5.7/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2025 Q4)	Prior (2025 Q3)	Change
Funds Holding	37	20	85.0%
13F Shares	483K	374K	29.07%
Total Value	$374K	$222K	68.22%
New Positions	22	3	+19
Increased Positions	3	5	-2
Closed Positions	5	3	+2
Reduced Positions	7	2	+5
Total Calls	0	0	-
Total Puts	0	0	-
PUT/CALL Ratio	0.0	0.0	Bullish

Metric

All 13F Filers (2025 Q4)

Prior (2025 Q3)

Change

Funds Holding

85.0%

13F Shares

483K

374K

29.07%

Total Value

$374K

$222K

68.22%

New Positions

+19

Increased Positions

-2

Closed Positions

Reduced Positions

Total Calls

Total Puts

PUT/CALL Ratio

0.0

Bullish

Institutional Holders (2026 Q1)

37 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in GTBP. Verified SEC 13F-HR filings.

FILTER:All New Added To Reduced No Change | Overweight >5% | SHOW: Active managers + show index funds

Top 12 institutional holders of GTBP — 2025 Q4 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	SeaCrest Wealth Management, LLC	0.00%	50,000	$20K
2	Private Wealth Management Group, LLC	0.00%	20,000	$8K
3	Coston, McIsaac & Partners	0.00%	17,092	$6K
4	AM INVESTMENT STRATEGIES LLC	0.00%	15,000	$6K
5	Verdence Capital Advisors LLC	0.00%	12,000	$5K
6	PARSONS CAPITAL MANAGEMENT INC/RI	0.00%	10,900	$4K
7	West Financial Advisors, LLC	0.00%	2,500	$1K
8	Stone House Investment Management, LLC	0.00%	1,251	—
9	Prospera Financial Services Inc	0.00%	11,996	$5K
10	MassMutual Private Wealth & Trust, FSB	0.00%	3,000	$1K
11	Farther Finance Advisors, LLC	0.00%	3,000	$1K
12	Hilltop National Bank	0.00%	100	—

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — GT BIOPHARMA INC (GTBP)

What does the Smart Money Trend signal show for GTBP?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added GTBP than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for GTBP?

More buyers than sellers — 68% buying: Last quarter: 25 funds were net buyers (22 opened a brand new position + 3 added to an existing one). Only 12 were sellers (7 trimmed + 5 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for GTBP holders?

Smaller funds dominant — 16% AUM from top-100: 8 of 37 holders rank in the top 100 by AUM, but together hold only 16% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held GTBP?

Mostly new holders — 65% entered in last year: Only 0 funds (0%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

GT BIOPHARMA INC (GTBP)

Smart Money Signals — GTBP

Buying streak — 1 quarter in a row

At the ownership peak (100% of max)

Fast accumulation — +131% more funds vs a year ago

More buyers than sellers — 68% buying

More new buyers each quarter (+19 vs last Q)

Mostly new holders — 65% entered in last year

Value +68% but shares only +29% — price-driven

Acceleration phase — new buyers rushing in

Early stage — 68% of holders entered in last year

Smaller funds dominant — 16% AUM from top-100

Hedge Fund Ownership: GTBP

Market Analysis: GTBP

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: GTBP

Hedge Fund Positioning: GTBP

Statistics: GTBP

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q1)

Frequently Asked Questions — GT BIOPHARMA INC (GTBP)

Welcome to 13Foresight!